VRNA
Verona PharmaVRNA
VRNA
About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Employees: 209
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
467% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 15
44% more capital invested
Capital invested by funds: $3.19B [Q4 2024] → $4.58B (+$1.39B) [Q1 2025]
34% more funds holding
Funds holding: 192 [Q4 2024] → 257 (+65) [Q1 2025]
22% more funds holding in top 10
Funds holding in top 10: 23 [Q4 2024] → 28 (+5) [Q1 2025]
0.93% more ownership
Funds ownership: 10.48% [Q4 2024] → 11.41% (+0.93%) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 86
51% less call options, than puts
Call options by funds: $70.5M | Put options by funds: $144M
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$95
10%
downside
Avg. target
$118
12%
upside
High target
$170
62%
upside
10 analyst ratings
6 positive
60%
4 neutral
40%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 2%upside $107 | Neutral Downgraded | 14 Jul 2025 |
Wells Fargo Tiago Fauth | 2%upside $107 | Equal-Weight Downgraded | 10 Jul 2025 |
Jefferies Suji Jeong | 2%upside $107 | Hold Downgraded | 9 Jul 2025 |
Canaccord Genuity Edward Nash | 2%upside $107 | Hold Downgraded | 9 Jul 2025 |
Wolfe Research Andy Chen | 62%upside $170 | Outperform Initiated | 1 Jul 2025 |
Financial journalist opinion
Based on 24 articles about VRNA published over the past 30 days
Neutral
Zacks Investment Research
9 hours ago
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.
Positive
Zacks Investment Research
2 weeks ago
Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now
In a volatile market, low-beta picks like VIPS, ALKT, FUTU and VRNA offer investors stability with solid upside potential.
Positive
Zacks Investment Research
2 weeks ago
What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?
Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
2 weeks ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Verona Pharma plc (NASDAQ: VRNA ) related to its sale to Merck Sharp & Dohme LLC for $107.00 per American Depository Shares. Is it a fair deal?
Neutral
Business Wire
2 weeks ago
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depository Share that they own. KSF is seeking to determine whether this consideration and the process.
Positive
Reuters
3 weeks ago
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Positive
Bloomberg Markets and Finance
3 weeks ago
Merck to Buy Verona Pharma for Around $10 Billion
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
Neutral
Business Wire
3 weeks ago
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders. Halper Sadeh encourages Verona shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Verona and its.
Positive
Invezz
3 weeks ago
Two big reasons why buying Verona was crucial for Merck
Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the UK-based biotech firm known for its COPD drug Ohtuvayre. The $10 billion all-cash agreement values VRNA shares at $107 each, representing about a 23% premium on their previous close.
Positive
WSJ
3 weeks ago
Merck has struck a roughly $10 billion deal to buy Verona Pharma
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Charts implemented using Lightweight Charts™